LGMD2I: Causes, Symptoms, and Diagnosis

LGMD2I is a form of limb-girdle muscular dystrophy caused by mutations in the FKRP gene, which provides instructions for a protein involved in keeping muscle fibers structurally sound. The condition leads to progressive weakness that starts around the hips and shoulders, though the age it appears and how fast it progresses vary widely. Under a revised classification system adopted in 2018, LGMD2I is now officially designated LGMD R9 FKRP-related, but many clinicians and patient communities still use the older name.

The FKRP Gene and the Most Common Mutation

LGMD2I traces back to mutations in a single gene called FKRP (fukutin-related protein), located on chromosome 19. The gene’s protein product plays a key role in attaching sugar chains to a molecule called alpha-dystroglycan, which sits on the surface of muscle cells and anchors them to the surrounding structural scaffolding. When FKRP is faulty, those sugar chains are incomplete, and the anchor weakens. Over time, muscle fibers sustain damage they cannot fully repair, leading to the progressive weakness that defines the disease.¹

One specific mutation dominates the landscape. Known as c.826C>A (p.Leu276Ile), it is the single most frequently identified change in the FKRP gene among people with LGMD2I. Haplotype analysis suggests this variant may have arisen only once in human history and then spread through population migrations, explaining why it turns up in genetically diverse groups including Hutterites, Scandinavians, and other Northern European populations.² Because the disease follows autosomal recessive inheritance, a person needs two faulty copies of FKRP to develop symptoms. Carriers with one working copy are unaffected.

Who Gets LGMD2I and Where It Is Most Common

LGMD2I is most frequent in Northern European populations, a pattern driven by the geographic distribution of the c.826C>A variant.³ Denmark stands out with a prevalence roughly three to four times higher than that seen in other regions, making LGMD2I the most common limb-girdle subtype in that country.⁴ Norway likewise reports a notable cluster of cases. Outside Scandinavia, the condition is recognized across Europe, North America, and in isolated communities such as the Hutterites, but it becomes rarer in populations where the founder mutation is uncommon.

Because limb-girdle dystrophies are individually rare and often underdiagnosed, prevalence figures for LGMD2I in non-European populations remain uncertain. Some people live with mild symptoms for years before seeking evaluation, and genetic testing has only become widely accessible in the last two decades, so older prevalence estimates almost certainly undercounted cases.

When Symptoms Appear and What They Feel Like

The age at which LGMD2I makes itself known spans an enormous range. In one well-characterized cohort of 20 patients, onset occurred anywhere from age 2 to age 50, with a mean around 19 years. Half of those patients first noticed problems before age 15, while a few did not develop symptoms until their forties or fifties.⁵ This wide window means LGMD2I can present as a childhood muscle disease or as a puzzling new weakness in middle age.

Regardless of when it starts, the pattern of weakness is remarkably consistent. The hips and thighs are affected first: people often notice trouble climbing stairs, rising from a low chair, or keeping up with peers during physical activity. Shoulder girdle weakness tends to develop later and stays milder in comparison. The weakness is symmetrical, affecting both sides equally.⁵

One feature that frequently catches clinicians’ attention is calf hypertrophy, where the calves appear unusually large and muscular even as other muscles are weakening. This finding, combined with elevated blood levels of creatine kinase (a marker of muscle damage), can initially look a lot like a dystrophinopathy such as Becker muscular dystrophy.⁶ That clinical overlap is one reason genetic testing has become central to arriving at the right diagnosis.

How Fast the Disease Progresses

Progression in LGMD2I varies considerably from person to person, but on the whole the disease tends to advance slowly compared to more severe muscular dystrophies. In the same cohort mentioned above, 15 of 20 patients remained ambulatory, with ages ranging from 19 to 65 at last assessment. Five patients lost the ability to walk, doing so between ages 13 and 69.⁵ Those numbers illustrate the spectrum: some people retain functional walking into their sixties, while others reach wheelchair dependence as teenagers.

Loss of ambulation has a measurable impact on overall quality of life. A health-outcomes model estimated that people with LGMD2I accumulate roughly 32 to 35 quality-adjusted life years, with much of the reduction in quality tied to the period after independent walking is lost.⁷ Maintaining mobility as long as possible is a major goal of ongoing management.

Cardiac and Respiratory Complications

LGMD2I is not purely a skeletal muscle disease. The heart and the breathing muscles can both be affected, and these complications are among the most clinically important features to monitor because they can develop independently of how weak the limbs are.

On the cardiac side, some patients develop dilated cardiomyopathy, where the heart muscle weakens and the chambers enlarge. What makes this especially tricky is that the severity of heart involvement does not track reliably with how bad the skeletal muscle disease looks. A person with mild limb weakness can still develop serious heart problems, and vice versa.⁸ Autopsy and biopsy studies have confirmed this disconnect at the tissue level: in at least two documented cases, the damage to heart muscle was severe while the skeletal muscle showed only mild changes.⁹ The practical takeaway is that every person diagnosed with LGMD2I should have regular cardiac monitoring regardless of how strong their limbs seem.

Respiratory insufficiency is the other major concern. Breathing muscles, particularly the diaphragm, can weaken over time. In one study, close to half of patients had a forced vital capacity below 75 percent of what would be expected for their age and size, and this respiratory compromise did not correlate neatly with overall skeletal muscle weakness either.¹⁰ People with LGMD2I may not feel short of breath during daily activities but still have significantly reduced lung capacity, especially when lying flat. Regular pulmonary function testing, even in patients whose limb weakness seems stable, helps catch problems before they become emergencies.

Getting a Diagnosis

The path to an LGMD2I diagnosis typically involves several complementary tools, because no single test is definitive in isolation (apart from genetic confirmation). Clinicians usually work through a combination of blood work, muscle biopsy, imaging, and ultimately genetic sequencing.

Blood Tests

The first clue is often an elevated creatine kinase level on a routine blood draw. CK leaks out of damaged muscle fibers, so consistently high levels signal ongoing muscle injury. In pediatric and adult LGMD2I patients, CK is almost always raised, sometimes dramatically so. One study of Norwegian children with the condition found CK was consistently increased, with only one presymptomatic patient showing normal levels.¹¹ But elevated CK is not specific to LGMD2I; it appears in many forms of muscular dystrophy and even in some inflammatory muscle diseases, so further workup is always needed.

Muscle Biopsy

A biopsy of affected muscle can show a range of findings, from mild changes resembling a general myopathy to severe dystrophic features with substantial fibrosis and fiber degeneration. One consistent hallmark is reduced glycosylation of alpha-dystroglycan on the muscle fiber surface, detectable with specialized antibody staining.¹² The degree of that reduction tends to loosely track with disease severity. Patients with milder disease who carry two copies of the common Leu276Ile mutation typically show subtle changes, while compound heterozygotes carrying one common mutation and one more severe mutation often display a more obvious reduction.¹³

In the era of affordable genetic testing, some clinicians now skip the biopsy and go straight to sequencing, reserving the invasive procedure for cases where the genetic picture is ambiguous or when the clinical presentation overlaps with inflammatory myopathies that would require different treatment.

Genetic Sequencing

Confirming LGMD2I ultimately requires identifying two pathogenic mutations in the FKRP gene. Whole-exome sequencing has become a common first-line tool for diagnosing limb-girdle dystrophies in general, since it can screen dozens of candidate genes at once. However, the FKRP gene has proven to be a special challenge for some sequencing platforms: at least one study found that whole-exome sequencing did not achieve good coverage of FKRP, and Sanger sequencing of the full gene was needed to pick up the second variant in a family.¹⁴ Clinicians who strongly suspect LGMD2I based on clinical features or ancestry may opt for targeted Sanger sequencing of FKRP alongside or instead of broader panels to avoid missing a mutation.

Muscle MRI Patterns

Muscle MRI has emerged as a valuable non-invasive tool both for supporting the diagnosis and for differentiating LGMD2I from other limb-girdle subtypes. On MRI, affected muscles show fatty infiltration, where normal muscle tissue is progressively replaced by fat, appearing as bright signal on certain imaging sequences.

In LGMD2I, the pattern follows a recognizable trajectory. Fatty changes typically appear first in the posterior thigh muscles, particularly the biceps femoris, semimembranosus, and semitendinosus, along with the adductor magnus.¹⁵ As the disease progresses, the anterior thigh gradually becomes involved while certain muscles, particularly the rectus femoris, sartorius, and gracilis, tend to be relatively spared.¹⁶ One study described a distinctive concentric pattern of fatty infiltration, most prominent in the vastus intermedius and vastus medialis near the knee, that was characteristic of LGMD2I patients carrying a specific FKRP founder mutation.¹⁶

These imaging patterns help clinicians narrow the differential. LGMD2I can look similar to LGMD2A (calpainopathy) on MRI because both show predominant posterior thigh involvement. A key distinguishing feature is the lower leg: LGMD2A tends to selectively involve the medial gastrocnemius and soleus, while LGMD2I does not show that selective pattern.¹⁷ Sarcoglycanopathies and Becker muscular dystrophy, by contrast, tend to hit the anterior thigh muscles harder, making them easier to distinguish from LGMD2I on imaging alone.¹⁷

Why the Severity Varies So Much

One of the more frustrating aspects of LGMD2I for both patients and clinicians is the enormous range in how the disease manifests. Two people with mutations in the same gene can have dramatically different experiences. The primary driver of this variability appears to be the specific combination of mutations each person carries.

People who are homozygous for the common Leu276Ile mutation, meaning they have two copies of that same milder variant, generally have a later onset and slower progression. Most patients with adult-onset, slowly progressive disease fall into this group.⁶ By contrast, compound heterozygotes who carry one copy of the common mutation paired with a more disruptive change (a different missense mutation or a nonsense mutation that truncates the protein) tend to present earlier in childhood and follow a more aggressive course that can resemble Duchenne-like severity.¹³

This genotype-phenotype pattern makes intuitive sense. The Leu276Ile change is a relatively conservative amino acid substitution that still allows the FKRP protein to retain some function. Two copies of it leave the cell with a partial ability to glycosylate alpha-dystroglycan, slowing the cascade of muscle damage. A more severe second mutation, however, can push the system past a threshold where glycosylation drops too low to keep muscle stable. Mouse models carrying two copies of the Leu276Ile mutation develop only a mild, slowly progressive myopathy with measurable but gradual loss of glycosylation, supporting the idea that residual FKRP function is the key variable determining severity.¹⁸

Even within the same genotype, though, there can be variation. Some homozygous Leu276Ile patients do worse than others, hinting that additional genetic modifiers, physical activity levels, or other unknown factors also play a role. The mutations in FKRP set the broad trajectory, but they do not perfectly predict any individual’s outcome.

The Updated Name and Classification

If you have been researching this condition, you may have encountered the designation “LGMD R9 FKRP-related.” In 2018, an international workshop restructured the limb-girdle dystrophy naming system, replacing the old number-based scheme (where “2” meant autosomal recessive and the trailing letter indicated order of discovery) with a system that uses “R” for recessive or “D” for dominant, followed by a number and the causative gene name.¹⁹ Under this system, LGMD2I became LGMD R9 FKRP-related. Both names refer to exactly the same disease. The older name persists in much of the published literature and in patient communities, so you will see both used interchangeably for some time.

The reclassification also clarified that mutations in FKRP produce a spectrum of disorders beyond just limb-girdle dystrophy. At the more severe end, FKRP mutations can cause congenital muscular dystrophy with brain and eye abnormalities (Walker-Warburg syndrome and muscle-eye-brain disease), while at the mild end they can produce isolated elevated CK with minimal or no symptoms.²⁰ LGMD2I/R9 sits in the middle of this continuum. Understanding this broader spectrum can help families make sense of why the same gene can cause such different outcomes depending on which mutations are present.

Experimental Treatments on the Horizon

There is no approved disease-modifying treatment for LGMD2I as of now, but the research pipeline has become more active. Two main experimental approaches are furthest along in preclinical development: gene therapy using adeno-associated virus (AAV) vectors and supplementation with a sugar molecule called ribitol.

AAV gene therapy aims to deliver a working copy of the FKRP gene directly into muscle cells, potentially restoring normal glycosylation of alpha-dystroglycan. Ribitol takes a different approach: rather than replacing the faulty gene, it supplies an extra building block that the remaining partially functional FKRP protein can use to attach sugar chains more effectively. Because ribitol depends on residual FKRP function, it restores glycosylation to limited levels on its own. Researchers have found, however, that combining both strategies can be more effective than either alone, with the gene therapy restoring full transgene expression while ribitol provides additional support through the existing cellular machinery.²¹ This combination approach, demonstrated in animal models, raises the possibility of a synergistic therapy with both better efficacy and improved safety margins compared to high-dose gene therapy alone.

These treatments remain in preclinical and early clinical stages. The mouse model carrying the common Leu276Ile mutation has been a useful platform for testing interventions, since it develops a slowly progressive myopathy that mirrors the milder human phenotype.¹⁸ Translating results from mice to humans is always uncertain, but for a disease that until recently had no experimental therapeutics at all, the current pipeline represents real progress. In the meantime, management centers on physical therapy, assistive devices, and the cardiac and respiratory monitoring discussed earlier.